香港稳定币立法落地；国内创新药上市跑出加速度

Group 1: Stablecoin Regulation in Hong Kong - The Hong Kong government has officially enacted the "Stablecoin Regulation," establishing a licensing system for issuers of fiat-backed stablecoins, enhancing the regulatory framework for virtual asset activities in Hong Kong [3][4] - The regulation aims to address the volatility of cryptocurrencies and is seen as a bridge between traditional finance and the crypto world, with stablecoins currently representing over 8% of the total cryptocurrency market capitalization, valued at over $240 billion as of May 20, 2025 [3][4] - The regulation is expected to accelerate the compliant development of stablecoins, leading to growth in the RWA ecosystem, including issuers, custodial banks, investors, and blockchain technology [4] Group 2: Domestic Innovative Drugs Approval - On May 29, 2025, China’s National Medical Products Administration approved 11 innovative drugs, marking a significant milestone in the domestic innovative drug sector, with many being the first of their kind in the country [8] - From the beginning of 2025 to the end of May, a total of 53 new drugs were approved in China, with 30 being domestic innovations, covering various therapeutic areas including oncology and rare diseases [8] - The innovative drug sector is expected to undergo a valuation reshaping, with upcoming national medical insurance negotiations being a critical event for newly approved drugs to gain market access and accelerate sales [8]